MedTech Industry Dynamics
MedTech Industry Dynamics
Medtronic has received CE Mark for its Vitalis portfolio of cardiac devices, including the ReSyncra CSP, Restoria CSP, Refina CSP, Effectra, and Confirma pacemakers, offering a suite of pacing options with features purpose-built for conduction system pacing therapy.
Read MoreMedtronic has completed the separation of MiniMed Group, with Medtronic exchanging all of its remaining interest in the diabetes business, which begins its first day as a fully independent company trading on Nasdaq under the ticker MMED.
Read MoreMedtronic has received FDA clearance and CE Mark for its Affera Prism-2 Mapping Software, along with CE Mark for the PulseSelect ProxBox Adapter with Proximity Indicator software, expanding integrated mapping and tissue-proximity capabilities across its cardiac ablation portfolio.
Read MoreMedtronic has received FDA Breakthrough Device designation for its investigational IN.PACT BTK Paclitaxel Drug-Coated Balloon Catheter, which will be studied in the IN.PACT BTK DELTA randomized pivotal trial of approximately 400 patients with below-the-knee lesions.
Read MoreMedtronic has launched ApexCut blades in Japan, a next-generation powered ENT instrumentation designed to reduce clogging and improve surgical efficiency in paranasal sinus surgery, following regulatory approval in May 2026.
Read MoreMedtronic has received FDA clearance for the LigaSure RAS Maryland jaw device for use with the Hugo robotic-assisted surgery system, bringing the company’s vessel-sealing technology used in more than 45 million procedures worldwide to U.S. robotic-assisted surgery.
Read MoreMedtronic has commenced an exchange offer to split off at least 80.1% of MiniMed Group shares, allowing Medtronic shareholders to exchange their ordinary shares for MiniMed common stock at a 7% discount in a transaction expected to be generally tax-free for U.S. federal income tax purposes.
Read MoreMedtronic has received CE Mark approval for its Endurant stent graft system to remove the ruptured abdominal aortic aneurysms (rAAA) treatment warning, following U.S. FDA labeling approval in October 2025, extending updated labeling to support expanded training and education in Europe.
Read MoreMedtronic announced a strategic investment of up to $80 million in Pi-Cardia to support its ShortCut leaflet modification device for valve-in-valve transcatheter aortic valve replacement (TAVR) procedures, with the option to acquire Pi-Cardia upon achievement of predefined milestones.
Read MoreCornerstone Robotics has announced a strategic partnership with Medtronic, including a $700 million investment and distribution rights for the Sentire surgical system in select markets outside the U.S., aiming to expand global access to robotic-assisted surgery.
Read More
